## CRSP: CRISPR Therapeutics AG - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 3.2% below STRENGTH zone (4.0-10.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($49.03)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 4)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-26 | Chardan Capital | $74 | $82 | -10% |
| 2025-11-12 | Citigroup | $77 | $87 | -11% |
| 2025-11-11 | RBC Capital | $50 | $42 | +19% |
| 2025-11-11 | Baird | $44 | $52 | -15% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-26 | Chardan Capital | main | Buy |
| 2025-11-12 | Citigroup | main | Buy |
| 2025-11-11 | RBC Capital | main | Sector Perform |
| 2025-11-11 | Baird | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 5 ($0.00M) |
| Sells | 5 ($3.81M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- ARK Investment Manag: 10.3% (-3.9%)
- Blackrock Inc.: 7.4% (+16.2%)
- Capital Internationa: 5.9% (+1.0%)
- Orbis Allan Gray Ltd: 5.2% (+80.2%)
- State Street Corpora: 4.2% (+22.5%)

### Key Risks

1. Insider selling cluster: $3.8M in recent transactions.
2. High short interest (25.8%, 10.4 days to cover): squeeze risk or crowded bearish bet.
3. Near-term weakness: 9.1% below SMA50 despite long-term uptrend.

### Catalysts

- Momentum building: MRS_20 improving +6.4% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

Balance sheet: strong liquidity (16.2x), low leverage (D/E 0.17). Revenue growth strong at 1916% YoY. Analyst sentiment negative (4 target cuts vs 1 raises). Insider selling cluster ($3.8M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $5.2B |
| Beta | 1.73 |
| 52W Range | $30.04 - $78.48 |
| Short Interest | 25.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.21 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 strengthening from -3.2% to 3.2% (+6.4% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.8pp (needs >4.0% for momentum thesis). MRS_5 at 4.6% confirms short-term momentum alignment. AM_20 at 5.2% shows strong absolute momentum above own 20MA. Outperforming sector by 3.5pp, stock-specific strength. MACD histogram positive (0.65), confirming momentum. RSI neutral at 51. OFD pattern: +FTL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 3.24% (CS: 79) | Neutral |
| RSI_14 | 50.6 | Neutral |
| MACD Histogram | 0.65 | Bullish |
| vs SMA20 | 1.052x | Above |
| vs SMA50 | 0.909x | Below |
| vs SMA200 | 1.110x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $55.99
- **Stop Loss:** $49.03 (12.4% risk)
- **Target:** $62.95 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 136
- **Position Value:** $7,614.64
- **Portfolio %:** 7.61%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-02-18 (Est: $-1.23)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.29 | $-1.17 | +9.2% |
| 2025Q2 | $-1.40 | $-1.29 | +7.8% |
| 2025Q1 | $-1.28 | $-1.58 | -23.8% |
| 2024Q4 | $-1.19 | $-0.44 | +62.9% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*